A new class of antibiotics has shown promising results in initial studies against an antibiotic-resistant bacterium. However, the active substance that researchers at the pharmaceutical company Roche in Basel have developed is still far from being used in practice.
According to the study published Wednesday in the journal Nature, the newly developed active ingredient zosurabalpine worked in the laboratory and in mice against the antibiotic-resistant bacterium Acinetobacter baumannii – a typical hospital germ that can cause pneumonia.
“Any new class of antibiotics that can treat infections caused by multidrug-resistant bacteria such as carbapenem-resistant Acinetobacter baumannii would be a major breakthrough,” said Roche’s Michael Lobritz, who was involved in the study, when asked by Keystone News Agency -SDA announces this.
However, further research is needed to know whether zosurabalpine will make this breakthrough.
(hah/sda)
source: watson
I’m Maxine Reitz, a journalist and news writer at 24 Instant News. I specialize in health-related topics and have written hundreds of articles on the subject. My work has been featured in leading publications such as The New York Times, The Guardian, and Healthline. As an experienced professional in the industry, I have consistently demonstrated an ability to develop compelling stories that engage readers.
